Phaseline

Targets › GPR35

GPR35 (G protein-coupled receptor 35): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2027.

G protein-coupled receptor that binds to several ligands including the tryptophan metabolite kynurenic acid (KYNA), lysophosphatidic acid (LPA) or 5-hydroxyindoleacetic acid (5-HIAA) with high affinity, leading to rapid and transient activation of numerous intracellular signaling pathways. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and…. (UniProt, Q9HC97)

Open in Phaseline: the race on GPR35, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Crossignal TherapeuticsCT3001
GPR35 inhibitor
GPR35Phase 1Solid Tumor, AdultJun 2027

Conditions

Solid Tumor, Adult (1)

Modalities

small molecule (1)

Companies

Crossignal Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.